BiotechTube
Acadia Pharmaceuticals

Acadia Pharmaceuticals

ACADApproved
San Diego, United StatesFounded 1993500-1000 employeesacadia.com

Acadia Pharmaceuticals is dedicated to advancing care for patients with neurological disorders and rare diseases who have few or no treatment options. The company has successfully brought two FDA-approved therapies to market: NUPLAZID® (pimavanserin) for Parkinson's disease psychosis and DAYBUE® (trofinetide) for Rett syndrome. Acadia maintains a clinical pipeline focused on expanding indications for its core assets and developing novel treatments for conditions like Alzheimer's disease psychosis. The company operates with a patient-centric approach, targeting complex care areas where significant unmet medical needs exist.

Market Cap
$3.6B
+22.7% period
Pipeline
48
23 in Phase 3
Patents
20
granted
Publications
20
indexed

ACAD · Stock Price

USD 20.99+3.88 (+22.68%)

Historical price data

AI Company Overview

Acadia Pharmaceuticals is dedicated to advancing care for patients with neurological disorders and rare diseases who have few or no treatment options. The company has successfully brought two FDA-approved therapies to market: NUPLAZID® (pimavanserin) for Parkinson's disease psychosis and DAYBUE® (trofinetide) for Rett syndrome. Acadia maintains a clinical pipeline focused on expanding indications for its core assets and developing novel treatments for conditions like Alzheimer's disease psychosis. The company operates with a patient-centric approach, targeting complex care areas where significant unmet medical needs exist.

Neurological DisordersRare DiseasesNeuropsychiatryParkinson's DiseaseRett SyndromeAlzheimer's DiseaseSchizophreniaPrader-Willi Syndrome

Technology Platform

Acadia employs targeted drug discovery focused on novel mechanisms in neuroscience, including selective serotonin receptor modulation (pimavanserin) and neurotrophic factor enhancement (trofinetide), without a single proprietary platform technology.

Pipeline

48
48 drugs in pipeline23 in Phase 3
DrugIndicationStageWatch
PimavanserinInsomnia ChronicApproved
PimavanserinParkinson Disease PsychosisApproved
PimavanserinNeurodegenerative DiseasesApproved
Pimavanserin + PlaceboNeuropsychiatric Symptoms Related to Neurodegenerative DiseasePhase 3
Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP...Parkinson's Disease PsychosisPhase 3

Funding History

4
Total raised:$82M
IPO$40MNov 19, 2004
Series B$30MJun 15, 2000
Series A$10MJun 15, 1997
Seed$2MJun 15, 1993

FDA Approved Drugs

4
DAYBUE STIXNDADec 11, 2025
DAYBUENDAMar 10, 2023
NUPLAZIDNDAJun 28, 2018

Opportunities

Acadia has significant growth opportunities through geographic expansion of its approved products, label expansion of pimavanserin into Alzheimer's disease psychosis (a multi-billion dollar market), and development of its pipeline in rare neurological disorders.
The company's first-mover advantage in both Parkinson's disease psychosis and Rett syndrome provides strong market positions with limited competition.

Risk Factors

Key risks include regulatory challenges for DAYBUE® in Europe, clinical trial failures in Alzheimer's disease psychosis development, dependence on NUPLAZID® for majority of revenue, pricing pressure, and competition from off-label generic antipsychotics.
The company also faces inherent risks in CNS drug development with high failure rates.

Competitive Landscape

Acadia faces limited direct competition in its approved indications but competes with off-label antipsychotics in Parkinson's disease psychosis. In Alzheimer's disease psychosis, competitors include Biogen/Eisai, Eli Lilly, Axsome Therapeutics, and Otsuka/Lundbeck. Acadia differentiates through selective mechanisms avoiding dopamine blockade and first-in-class status in rare neurological disorders.